In 2019, the global biopharmaceutical giant's R & D return rate is only 1.8%, the lowest in ten years!

Compile newborn In the past decade, increasing pressure has weakened the productivity of biopharmaceutical research and development, resulting in a sustained decline in return on investment, Deloitte said in a recent report At the same time, innovative therapies are changing the face of disease management New treatment models and increasing understanding of precision medicine have led to the demand for new research and development models and a more participatory, preventive and personalized future for medicine The report points out that according to the analysis of the first nine years of the "evaluation of the return on pharmaceutical innovation" series, it is concluded that the transformation of R & D productivity is necessary to reverse the declining trend of R & D return in the whole biopharmaceutical industry, which is still correct today According to the report, in 2019, it is at the lowest level in 10 years, which is 0.1% lower than 2018, but significantly lower than 10.1% in 2010 In 2013, the added second tier four biopharmaceutical companies (Aberdeen, Xinji, Bojian and gillide) performed better than the top 12 giants, but they still faced similar productivity challenges and reduced returns In addition, the growth rate is 67% compared with us $1188 million in 2010 In 2019, the average forecast peak sales of each later pipeline asset fell below $400 million for the first time, from $407 million in 2018 to $376 million in 2019, a decrease of more than 50% compared with 2010 The report also points out that lower returns are a common result of internal and external productivity challenges In recent years, the number of pipeline assets in the later stage of Top12 company has gradually decreased, reaching the lowest point of 159 in 2018, with an average of 13.25 for each However, in 2019, these companies have supplemented later pipelines, and the number of assets has increased to 183, a three-year high, which is very close to the 10-year average of 186.5 Looking to the future, biopharmaceuticals will focus on the development of therapies for a variety of diseases that still lack drugs, as well as the creation of more accurate treatment options for smaller populations or individual patients The development of these therapies presents new challenges, with the development of biologics targeted at smaller patient groups being more costly, time-consuming and generating less revenue.